Literature DB >> 9562476

Possible role of tau protein kinases in pathogenesis of Alzheimer's disease.

K Imahori1, M Hoshi, K Ishiguro, K Sato, M Takahashi, R Shiurba, H Yamaguchi, A Takashima, T Uchida.   

Abstract

Tau protein kinases (TPK) I and II were isolated as candidate enzymes responsible for the hyperphosphorylation observed in PHF-tau. Four phosphorylation sites of tau were identified for each kinase, accounting for most, but not all, of the major phosphorylation sites of PHF-tau. Immunostaining with anti-TPKI antibody indicated that this kinase is up-regulated in AD brain. Such up-regulation of TPKI and phosphorylatioin of tau were reproduced by treating cultured hippocampal cells with amyloid beta (Abeta) protein. In addition, we found that TPKI can phosphorylate and inactivate pyruvate dehydrogenase (PDH), which is expected to result in depletion of acetyl-CoA, a key substrate of acetyl choline synthesis. Indeed, when septum cells were treated with Abeta, the level of acetyl choline decreased dramatically.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562476     DOI: 10.1016/s0197-4580(98)00025-6

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  10 in total

1.  Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice.

Authors:  V Askanas; W K Engel
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

2.  Bioenergetics breakdown in Alzheimer's disease: targets for new therapies.

Authors:  Uday Saxena
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-06-12

3.  The expression of Cdk5, p35, p39, and Cdk5 kinase activity in developing, adult, and aged rat brains.

Authors:  D C Wu; Y P Yu; N T Lee; A C Yu; J H Wang; Y F Han
Journal:  Neurochem Res       Date:  2000-07       Impact factor: 3.996

4.  Alzheimer's Disease and Protein Kinases.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.

Authors:  Dylan W Peterson; D Michael Ando; Daryl A Taketa; Hongjun Zhou; Fredrick W Dahlquist; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

6.  Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity.

Authors:  Alexandra M Nicholson; Adriana Ferreira
Journal:  J Neurosci       Date:  2009-04-08       Impact factor: 6.167

7.  Neuroprotective properties of valproate: potential benefit for AD and tauopathies.

Authors:  Rebekah Loy; Pierre N Tariot
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

Review 8.  Intracellular A-beta amyloid, a sign for worse things to come?

Authors:  Valentina Echeverria; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

9.  The Toll-->NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in Drosophila.

Authors:  Lihua Tan; Paul Schedl; Ho-Juhn Song; Dan Garza; Mary Konsolaki
Journal:  PLoS One       Date:  2008-12-17       Impact factor: 3.240

Review 10.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.